Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.34 |
| ▸ | BTK | Q06187 | 7/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766704 | 0.96 | BUB1 (0.34) | SYKCTSKBUB1CTSLCTSB | |
| SCHEMBL3763755 | 0.94 | ALDH1A1 (0.34) | SYKBTK | |
| SCHEMBL3765171 | 0.91 | SYK (0.35) | SYKCTSKBUB1CTSLCTSB | |
| SCHEMBL3764960 | 0.90 | CTSK (0.34) | CTSKBUB1CTSLCTSBCTSS | |
| SCHEMBL3763951 | 0.90 | EPHX2 (0.37) | SYK | |
| SCHEMBL3757464 | 0.89 | BUB1 (0.34) | SYKBTKBUB1 | |
| SCHEMBL3760371 | 0.88 | BMPR1B (0.39) | SYKBUB1 | |
| SCHEMBL3760091 | 0.88 | CTSK (0.33) | CTSKBUB1CTSLCTSBCTSS | |
| SCHEMBL3767336 | 0.88 | POLB (0.35) | CTSKBUB1CTSLCTSBCTSS | |
| SCHEMBL3759732 | 0.87 | ALDH1A1 (0.33) | SYKBUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | SYK 201/4885BTK 19/4885CTSK 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.